Now, findings from the Stanford University School of Medicine and Lucile Packard Children's Hospital shed light on the neural basis of memory defects in Down syndrome and suggest a new strategy for treating the defects with medication.
The study, which was conducted in mice, is the first to show that boosting norepinephrine signaling in the brains of mice genetically engineered to mimic Down syndrome improves their cognition. Norepinephrine is a neurotransmitter that nerve cells use to communicate.
"If you intervene early enough, you will be able to help kids with Down syndrome to collect and modulate information," said Ahmad Salehi, MD, PhD, the primary author of the study, which will be published Nov. 18 in Science Translational Medicine. "Theoretically, that could lead to an improvement in cognitive functions in these kids." Salehi, a research health science specialist at the Veterans Affairs Palo Alto Health Care System, was a senior scientist at the School of Medicine when the study was conducted.
Down syndrome is a genetic disorder caused by an extra copy of chromosome 21. Using a mouse model, Salehi and his colleagues are examining exactly how the brain malfunctions in Down syndrome. "Cognition doesn't fail in every aspect; it's failing in a structure-dependent fashion," he said.
For instance, people with Down syndrome struggle to use spatial and contextual information to form new memories, a function that depends on the hippocampus part of the brain. As a result, they have trouble with learning to navigate complex environments such as a new neighborhood or a shopping mall. But they're much better at remembering information linked to colors, sounds or other sensory cues because such sensory memories are coordinated by a different brain structure, the amygdala.
Salehi and his colleagues looked at what could be causing the problems in the hippocampus. Normally, as contextual or relational memories are formed, hippocampal neurons receive norepinephrine from neurons in another part of the brain, the locus coeruleus. The researchers showed that, like humans with Down syndrome, the mice in their experiments experienced early degeneration of the locus coeruleus.
When the locus coeruleus broke down in the study's mice, the animals failed at simple cognitive tests that required them to be aware of changes in the milieu: For instance, the genetically engineered mice, when placed in the strange environment of an unknown cage, did not build nests. That contrasts with normal mice, which typically build nests in such circumstances.
However, by giving norepinephrine precursors to the mice with the Down-syndrome-like condition, the researchers could fix the problem. Only a few hours after they got the drugs, which were converted to norepinephrine in the brain, these mice were just as good at nest-building and related cognitive tests as normal mice. Direct examination of neurons in the hippocampus of the genetically altered mice showed that these cells responded well to norepinephrine.
"We were very surprised to see that, wow, it worked so fast," Salehi said. The drugs' effect also wore off relatively quickly, he added.
Enhancement of norepinephrine signaling has been explored for other neurological conditions. Some of the drugs already on the market for depression and attention deficit hyperactivity disorder target the norepinephrine system; Salehi hopes the new results will spur tests of these drugs for Down syndrome.
Other studies of drug therapies for Down syndrome have targeted a different neurotransmitter, acetylcholine, which also acts at the hippocampus. Based on his team's new findings, Salehi said the ideal medication regimen for improving cognition in Down syndrome will likely improve both norepinephrine and acetylcholine signals.
The new study also provides the first direct link between locus coeruleus breakdown in Down syndrome and a specific gene. People with Down syndrome have an extra copy of a gene called APP on their extra chromosome 21. Other researchers have linked APP to Alzheimer's disease, another disorder in which spatial orientation and memory formation go awry. Salehi and colleagues previously linked APP to the breakdown of neurons that make acetylcholine in these mice.
Salehi's results give "a ray of hope and optimism for the Down syndrome community for the future," said Melanie Manning, MD, director of the Center for Down Syndrome at Lucile Packard Children's Hospital. Manning was not a part of Salehi's research team. "It's very exciting," she said. "We still have a long way to go, but these are very interesting results."
Salehi's collaborators at Stanford included life-science research assistants Mehrdad Faizi, PhD, Janice Valletta and R. Takimoto-Kimura; research associates Damien Colas, PhD, and Alexander Kleschevnikov, PhD; Jessenia Laguna, visiting fellow; Mehrdad Shamloo, PhD, senior research scientist; and former director of the Stanford Institute for Neuro-Innovation & Translational Neurosciences William Mobley, MD, PhD, who is now at the University of California-San Diego. Mobley had also been director of Packard Children's Center for Down Syndrome.
The research was funded by grants from the National Institutes of Health, the Larry L. Hillblom Foundation, the Down Syndrome Research and Treatment Foundation, the Thrasher Research Fund, Adler Foundation and the Alzheimer Association. The team has filed a patent application related to the research.
The Stanford University School of Medicine consistently ranks among the nation's top 10 medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://mednews.stanford.edu. The medical school is part of Stanford Medicine, which includes Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For information about all three, please visit http://stanfordmedicine.org/about/news.html.
Ranked as one of the best pediatric hospitals in the nation by U.S.News & World Report, Lucile Packard Children's Hospital at Stanford is a 272-bed hospital devoted to the care of children and expectant mothers. Providing pediatric and obstetric medical and surgical services and associated with the Stanford University School of Medicine, Packard Children's offers patients locally, regionally and nationally the full range of health-care programs and services — from preventive and routine care to the diagnosis and treatment of serious illness and injury. For more information, visit http://www.lpch.org.
Erin Digitale | EurekAlert!
Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University
Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
24.02.2017 | Life Sciences
24.02.2017 | Life Sciences
24.02.2017 | Trade Fair News